keyword
https://read.qxmd.com/read/38502058/immune-checkpoint-cd161-llt1-associated-immunological-landscape-and-diagnostic-value-in-oral-squamous-cell-carcinoma
#21
JOURNAL ARTICLE
Xinyang Hu, Yuexin Dong, Shixin Xie, Yuxian Song, Chenhang Yu, Yijia He, Zhiyong Wang, Qingang Hu, Yanhong Ni, Liang Ding
An active host adaptive response is characterized by the existence of programmed cell death protein 1 (PD-1)+ /IFN-γ+ cytotoxic T cells and IFN-γ-induced PD-L1+ tumor cells (TCs), which predicts high response rate to anti-PD-1/L1 therapy. Recently, CD161 and its ligand LLT1 (CLEC2D) have been identified as an emerging checkpoint for immunotherapy. Clarifying its heterogeneous clinical expression pattern and its immune landscape is a prerequisite for maximizing the response rate of CD161 blockade therapy in a specific population of oral squamous cell carcinoma (OSCC) patients...
March 2024: Journal of Pathology. Clinical Research
https://read.qxmd.com/read/38498870/performance-of-a-claims-based-frailty-proxy-using-varying-frailty-ascertainment-lookback-windows
#22
JOURNAL ARTICLE
Emilie D Duchesneau, Til Stürmer, Dae Hyun Kim, Katherine Reeder-Hayes, Jessie K Edwards, Keturah R Faurot, Jennifer L Lund
BACKGROUND: Frailty is an aging-related syndrome of reduced physiological reserve to maintain homeostasis. The Faurot frailty index has been validated as a Medicare claims-based proxy for predicting frailty using billing information from a user-specified ascertainment window. OBJECTIVES: We assessed the validity of the Faurot frailty index as a predictor of the frailty phenotype and 1-year mortality using varying frailty ascertainment windows. RESEARCH DESIGN: We identified older adults (66+ y) in Round 5 (2015) of the National Health and Aging Trends Study with Medicare claims linkage...
March 12, 2024: Medical Care
https://read.qxmd.com/read/38496688/systemic-immune-index-predicts-tumor-infiltrating-lymphocyte-intensity-and-immunotherapy-response-in-small-cell-lung-cancer
#23
JOURNAL ARTICLE
Chaoqiang Deng, Jiatao Liao, Zichen Fu, Fangqiu Fu, Di Li, Yuan Li, Jialei Wang, Haiquan Chen, Yang Zhang
BACKGROUND: Despite recent progresses in immune checkpoint blockade (ICB) in small-cell lung cancer (SCLC), a lack of understanding regarding the systemic tumor immune environment (STIE) and local tumor immune microenvironment (TIME) makes it difficult to accurately predict clinical outcomes and identify potential beneficiaries from ICB therapy. METHODS: We enrolled 191 patients with stage I-III SCLC and comprehensively evaluated the prognostic role of STIE by several quantitative measurements, and further integrate it with a local immune score system (LISS) established by eXtreme Gradient Boosting (XGBoost) machine learning algorithm...
February 29, 2024: Translational Lung Cancer Research
https://read.qxmd.com/read/38496282/development-of-korean-representative-headforms-for-the-total-inward-leakage-testing-on-filtering-facepiece-respirators
#24
JOURNAL ARTICLE
Ah Lam Lee, Xin Cui, Hayoung Jung, Hee Eun Kim, Eun Jin Jeon, Hyungjin Na, Eunmi Kim, Heecheon You
BACKGROUND: The lack of headforms that accurately reflect the head characteristics of Koreans and the demographic composition of the Korean population can lead to inadequate FFR testing and reduced effectiveness of FFRs. METHOD: Direct measurements of 5,110 individuals and 3D measurements of 2,044 individuals, aged between 9 and 69 years, were sampled from the data pool of Size Korea surveys based on the age and gender ratios of the Korean resident demographics...
March 2024: Safety and Health At Work
https://read.qxmd.com/read/38495487/cmtm6-a-critical-prognostic-indicator-in-non-small-cell-lung-cancer
#25
JOURNAL ARTICLE
Fang Dai, Yu-Lian Duan, Qiang Feng, Shu-Ling Song, Ju-Lun Yang, Tao Lv
While CKLF-like MARVEL transmembrane domain containing 6 (CMTM6)'s role in stabilizing PD-L1 and immune evasion within tumors is established, its expression in lung cancer tissue and adjacent macrophages remains uncertain. The study aimed to elucidate this ambiguity by investigating CMTM6's role in non-small cell lung cancer (NSCLC) prognosis. Employing immunohistochemical staining on 141 NSCLC and 110 adjacent normal lung tissue samples, CMTM6 expression was evaluated using the HSCORE system. Interestingly, NSCLC exhibited significantly higher CMTM6 levels (161...
2024: Journal of Cancer
https://read.qxmd.com/read/38495199/tumor-infiltrating-cd8-sub-populations-in-primary-and-recurrent-glioblastoma-an-in-silico-study
#26
JOURNAL ARTICLE
Mahdi Abdoli Shadbad, Adib Miraki Feriz, Behzad Baradaran, Hossein Safarpour
BACKGROUND: Glioblastoma multiforme (GBM) remains an incurable primary brain tumor. CD8+ tumor-infiltrating lymphocytes (TILs) can target malignant cells; however, their anti-tumoral immune responses mostly do not lead to GBM rejection in GBM patients. We profiled the sub-populations of tumor-infiltrating CD8+ T-cells, i.e., naïve, cytotoxic, and exhausted cells, in primary and recurrent GBM tissues and provided a blueprint for future precision-based GBM immunotherapy. METHOD: We re-analyzed the raw data of single-cell RNA sequencing on the cells residing in the GBM microenvironment and leveraged tumor bulk RNA analyses to study the significance of CD8+ TILs sub-populations in primary and recurrent GBM...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38492474/fertility-potential-and-safety-assessment-of-residual-ovarian-cortex-in-young-women-diagnosed-with-epithelial-borderline-and-early-stage-malignant-ovarian-tumors
#27
JOURNAL ARTICLE
L Cacciottola, A Camboni, E Gatti, E Marbaix, M Vignali, J Donnez, M M Dolmans
OBJECTIVE: To establish the safety and quality of ovarian cortex surrounding epithelial ovarian tumors in women eligible for fertility-sparing surgery by identifying occult malignant lesions and characterizing the ovarian follicle pool. METHODS: Multicentric retrospective study of 48 subjects (15-45 years), diagnosed with borderline ovarian tumors (BOTs) or early-stage epithelial ovarian cancers (EOCs) and eligible for fertility-sparing surgery. Histological samples of ovarian cortex surrounding tumors were analyzed to characterize the follicle pool, find any occult malignant lesion using tumor-specific markers (cytokeratin 7 and mucin 1), and quantify tumor-infiltrating lymphocytes (TILs) by CD3 and tumor associated macrophages (TAMs) by CD68...
March 15, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38491286/world-s-first-til-therapy-approved
#28
(no author information available yet)
No abstract text is available yet for this article.
March 2024: Nature Biotechnology
https://read.qxmd.com/read/38490211/acetyl-coa-carboxylase-obstructs-cd8-t%C3%A2-cell-lipid-utilization-in-the-tumor-microenvironment
#29
JOURNAL ARTICLE
Elizabeth G Hunt, Katie E Hurst, Brian P Riesenberg, Andrew S Kennedy, Evelyn J Gandy, Alex M Andrews, Coral Del Mar Alicea Pauneto, Lauren E Ball, Emily D Wallace, Peng Gao, Jeremy Meier, John J Serody, Michael F Coleman, Jessica E Thaxton
The solid tumor microenvironment (TME) imprints a compromised metabolic state in tumor-infiltrating T cells (TILs), hallmarked by the inability to maintain effective energy synthesis for antitumor function and survival. T cells in the TME must catabolize lipids via mitochondrial fatty acid oxidation (FAO) to supply energy in nutrient stress, and it is established that T cells enriched in FAO are adept at cancer control. However, endogenous TILs and unmodified cellular therapy products fail to sustain bioenergetics in tumors...
March 11, 2024: Cell Metabolism
https://read.qxmd.com/read/38485189/pembrolizumab-versus-placebo-as-adjuvant-therapy-in-resected-stage-iib-or-iic-melanoma-outcomes-in-histopathologic-subgroups-from-the-randomized-double-blind-phase-3-keynote-716-trial
#30
JOURNAL ARTICLE
Dirk Schadendorf, Jason John Luke, Paolo A Ascierto, Georgina V Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz-Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
BACKGROUND: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified third interim analysis (data cut-off, January 4, 2022), the HR for RFS in the overall population was 0.64 (95% CI, 0.50 to 0.84) and the HR for DMFS was 0.64 (95% CI, 0.47 to 0.88). We present a post hoc analysis of efficacy by subtypes defined by histopathologic characteristics...
March 13, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38485186/biomarkers-for-response-to-til-therapy-a-comprehensive-review
#31
REVIEW
Víctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj, Troels Holz Borch, Marco Donia, Inge Marie Svane
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding and logistically complex treatment, extensive preclinical and clinical effort is required to optimize patient selection by identifying predictive biomarkers of response. This review aims to comprehensively summarize the current evidence regarding the potential impact of tumor-related factors (such as mutational burden, neoantigen load, immune infiltration, status of oncogenic driver genes, and epigenetic modifications), patient characteristics (including disease burden and location, baseline cytokines and lactate dehydrogenase serum levels, human leucocyte antigen haplotype, or prior exposure to immune checkpoint inhibitors and other anticancer therapies), phenotypic features of the transferred T cells (mainly the total cell count, CD8:CD4 ratio, ex vivo culture time, expression of exhaustion markers, costimulatory signals, antitumor reactivity, and scope of target tumor-associated antigens), and other treatment-related factors (such as lymphodepleting chemotherapy and postinfusion administration of interleukin-2)...
March 13, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38482921/cyclin-dependent-kinase-inhibitors-enhance-programmed-cell-death-protein-1-immune-checkpoint-blockade-efficacy-in-triple-negative-breast-cancer-by-affecting-the-immune-microenvironment
#32
JOURNAL ARTICLE
Jiayi Wu, Wei Wang, Lu Gao, Xiying Shao, Xiaojia Wang
BACKGROUND: Clinical studies on programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors for treating triple-negative breast cancer (TNBC) have shown unsatisfactory efficacy due to low tumor-infiltrating lymphocyte (TIL) levels. Inhibitors targeting cyclin-dependent kinase (CDK) proteins can affect the immune microenvironment, increase TIL levels, and promote antitumor immunity, thus providing a new direction for TNBC treatment strategies. METHODS: The authors tested three CDK inhibitors on the TNBC cell lines MDA-MB-231 and 4T1 and validated their antitumor effects and impact on the immune microenvironment using multiple detection methods...
March 14, 2024: Cancer
https://read.qxmd.com/read/38481730/prognostic-impact-of-the-bone-marrow-tumor-microenvironment-hla-i-and-hla-ib-expression-in-mds-and-cmml-progression-to-saml
#33
JOURNAL ARTICLE
Marcus Bauer, Nadja Jäkel, Andreas Wilfer, Anja Haak, Markus Eszlinger, Katalin Kelemen, Monika Haemmerle, Haifa Kathrin Al-Ali, Barbara Seliger, Claudia Wickenhauser
Genetic aberrations and immune escape are fundamental in MDS and CMML initiation and progression to sAML. Therefore, quantitative and spatial immune cell organization, expression of immune checkpoints (ICP), classical human leukocyte antigen class I (HLA-I) and the non-classical HLA-Ib antigens were analyzed in 274 neoplastic and 50 non-neoplastic bone marrow (BM) biopsies using conventional and multiplex immunohistochemistry and correlated to publicly available dataset. Higher numbers of tissue infiltrating lymphocytes (TILs) were found in MDS/CMML (8...
2024: Oncoimmunology
https://read.qxmd.com/read/38476909/tumor-immunity-a-brief-overview-of-tumor%C3%A2-infiltrating-immune-cells-and-research-advances-into-tumor%C3%A2-infiltrating-lymphocytes-in-gynecological-malignancies-review
#34
REVIEW
Zi-Tao Wang, Zhi-Min Deng, Fang-Fang Dai, Meng-Qin Yuan, Shi-Yi Liu, Bing-Shu Li, Yan-Xiang Cheng
Tumor immunity is a promising topic in the area of cancer therapy. The 'soil' function of the tumor microenvironment (TME) for tumor growth has attracted wide attention from scientists. Tumor-infiltrating immune cells in the TME, especially the tumor-infiltrating lymphocytes (TILs), serve a key role in cancer. Firstly, relevant literature was searched in the PubMed and Web of Science databases with the following key words: 'Tumor microenvironment'; 'TME'; 'tumor-infiltrating immunity cells'; 'gynecologic malignancies'; 'the adoptive cell therapy (ACT) of TILs'; and 'TIL-ACT' (https://pubmed...
April 2024: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/38476043/durability-of-effects-of-cognitive-remediation-on-cognition-and-psychosocial-functioning-in-schizophrenia-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#35
JOURNAL ARTICLE
Antonio Vita, Stefano Barlati, Anna Ceraso, Gabriele Nibbio, Francesca Durante, Michele Facchi, Giacomo Deste, Til Wykes
OBJECTIVE: Cognitive remediation provides substantial improvements in cognitive performance and real-world functioning for people living with schizophrenia, but the durability of these benefits needs to be reassessed and better defined. The aims of this study were to provide a comprehensive assessment of the durability of the benefits of cognitive remediation for cognition and functioning in people living with schizophrenia and evaluating potential moderators of effects. METHODS: A systematic search was conducted in PubMed, Scopus, and PsycINFO, and reference lists of included articles and Google Scholar were inspected...
March 13, 2024: American Journal of Psychiatry
https://read.qxmd.com/read/38474415/building-a-better-defense-expanding-and-improving-natural-killer-cells-for-adoptive-cell-therapy
#36
REVIEW
Andreia Maia, Mubin Tarannum, Joana R Lérias, Sara Piccinelli, Luis Miguel Borrego, Markus Maeurer, Rizwan Romee, Mireia Castillo-Martin
Natural killer (NK) cells have gained attention as a promising adoptive cell therapy platform for their potential to improve cancer treatments. NK cells offer distinct advantages over T-cells, including major histocompatibility complex class I (MHC-I)-independent tumor recognition and low risk of toxicity, even in an allogeneic setting. Despite this tremendous potential, challenges persist, such as limited in vivo persistence, reduced tumor infiltration, and low absolute NK cell numbers. This review outlines several strategies aiming to overcome these challenges...
March 5, 2024: Cells
https://read.qxmd.com/read/38474285/the-transcriptional-landscape-of-immune-response-3-utr-alternative-polyadenylation-in-melanoma
#37
JOURNAL ARTICLE
Xiao Yang, Yingyi Wu, Xingyu Chen, Jiayue Qiu, Chen Huang
The prognosis of patients with malignant melanoma has been improved in recent decades due to advancements in immunotherapy. However, a considerable proportion of patients are refractory to treatment, particularly at advanced stages. This underscores the necessity of developing a new strategy to improve it. Alternative polyadenylation (APA), as a marker of crucial posttranscriptional regulation, has emerged as a major new type of epigenetic marker involved in tumorigenesis. However, the potential roles of APA in shaping the tumor microenvironment (TME) are largely unexplored...
March 6, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38468323/her2-low-and-tumor-infiltrating-lymphocytes-in-triple-negative-breast-cancer-are-they-connected
#38
MULTICENTER STUDY
Ximena Baez-Navarro, Nadine S van den Ende, Anh H Nguyen, Renata Sinke, Pieter Westenend, Johannes Bastiaan van Brakel, Claudia Stobbe, Johan Westerga, Carolien H M van Deurzen
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity. In addition, a novel antibody-drug conjugate, namely, trastuzumab-deruxtecan, has shown effectiveness in TNBC patients with low-HER2 expression (HER2-low). These novel treatment options raise the question about the potential association between the density of stromal tumor-infiltrating lymphocytes (sTILs) and the level of HER2 expression...
March 11, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38462397/long-term-outcomes-of-s-1-combined-with-low-dose-docetaxel-as-neoadjuvant-chemotherapy-n-1-study-phase-ii-trial-in-patients-with-operable-breast-cancer
#39
JOURNAL ARTICLE
Soichiro Sasa, Hiroaki Inoue, Misako Nakagawa, Hiroaki Toba, Masakazu Goto, Kazumasa Okumura, Mariko Misaki, Tomohiro Inui, Sawaka Yukishige, Aya Nishisho, Naoki Hino, Miyuki Kanematsu, Yoshimi Bando, Hisanori Uehara, Akira Tangoku, Hiromitsu Takizawa
BACKGROUND: We previously reported that S-1 and low-dose docetaxel (DOC) (N-1 study, phase II trial) could be a well-tolerated and effective neoadjuvant chemotherapies (NACs) for patients with operable breast cancer. Herein, we analyzed the long-term outcomes and developed clinicopathological and molecular predictors of pathological complete response (pCR). PATIENTS AND METHODS: Eighty-three patients received S-1 (40 mg/m2 orally on days 1-14) and DOC (40 mg/m2 intravenously on day 1) every 3 weeks for 4 to 8 cycles...
February 22, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38460250/comprehensive-genomic-profiling-to-identify-actionable-alterations-for-breast-cancer-brain-metastases-in-the-chinese-population
#40
JOURNAL ARTICLE
Q Lu, N Wang, K Jiang, H Zhou, P Zhang, J Zhang, S Wang, P Sun, F Xu
BACKGROUND: Breast cancer brain metastasis (BCBM) is a crucial issue in the treatment of breast cancer and is associated with poor prognosis. Therefore, novel therapeutic targets are urgently needed in clinical practice. In this study, we aimed to identify potential actionable targets in brain metastases (BMs) utilising the FoundationOne® CDx (F1CDx). PATIENTS AND METHODS: Formalin-fixed paraffin-embedded archived specimens including 16 primary breast tumours (PTs), 49 BCBMs and 7 extracranial metastases (ECMs) from 54 patients who underwent surgery for BCBM were tested using F1CDx...
March 8, 2024: ESMO Open
keyword
keyword
55769
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.